Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT

Bone Marrow Transplantation

Volumn 48, Issue 6, 2013, Pages 771-776

  Wood, W A ^a   Whitley, J ^a   Goyal, R ^a   Brown, P M ^b   Sharf, A ^a   Irons, R ^a   Rao, K V ^a   Essenmacher, A ^a   Serody, J S ^a   Coghill, J M ^a   Armistead, P M ^a   Sarantopoulos, S ^a   Gabriel, D A ^a   Shea, T C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

autologous transplantation; etoposide; lymphoma; outcomes

Indexed keywords

CD34 ANTIGEN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL READMISSION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; STEM CELL MOBILIZATION; T CELL LYMPHOMA;

ADULT; AGED; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTOGRAFTS; COSTS AND COST ANALYSIS; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 84879077911     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.216     Document Type: Article

References (22)

1. Pasquini MC, Wang Z, Horowitz MM, Gale RP. Current use and outcome of hematopoietic stem cell transplantation: Center for International Blood and Marrow Transplant Research (CIBMTR) Summary Slides 2010, Available at http://www.cibmtr.org.
2. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J clin oncol 2009; 27: 4767-4773.
3. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011; 46: 943-949.
4. Jagasia MH, Savani BN, Neff A, Dixon S, Chen H, Pickard AS. Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. Bone Marrow Transplant 2010; 46: 10848.
5. Heizmann M, O'Meara AC, Moosmann PR, Heijnen IA, Zuberbühler M, Fernandez P et al. Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma. Bone Marrow Transplant 2009; 44: 75-79.
6. Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S et al. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43: 101-105.
7. Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R et al. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia. Bone Marrow Transplant 2011; 47: 231-235.
8. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
9. Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 2011; 51: 1300-1313.
10. Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with 'poor' mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506-512.
11. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ et al. Effectiveness and cost analysis of 'just-in-time' salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; 51: 2175-2182.
12. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729-736.
13. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-69.
14. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523-528.
15. Wood WA, Whitley J, Moore D, Sharf A, Irons R, Rao K et al. Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy. Biol Blood Marrow Transplant 2011; 17: 141-146.
16. Bandarenko N, Sims LC, Brecher ME. Circulating CD34\+ cell counts are predictive of CD34\+ peripheral blood progenitor cell yields. Transfusion 1997; 37: 1218, author reply 1218-1220.
17. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-1593.
18. Gertz MA, Wolf RC, Micallef IN, Gastineau DA. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45: 1396-1403.
19. Nademanee AP, Dipersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(\+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(\+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 2012; 18: 1564-1572.
20. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-363.
21. Jantunen E, Kuittinen T, Mahlamaki E, Pyorala M, Mantymaa P, Nousiainen T. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011; 86: 299-304.
22. Basak GW, Urbanowska E, Boguradzki P, Torosian T, Halaburda K, Wiktor-Jedrzejczak W. Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure. Ann Transplant 2010; 15: 61-67.